Bacterial lipoprotein (BLP) is the most abundant protein in gram-negative bacterial cell walls, heavily outweighing lipopolysaccharide (LPS). Herein we present findings demonstrating the potent in vitro effects of BLP on neutrophil (PMN) activation status, function, and capacity to transmigrate an endothelial monolayer. PMNs are the principal effectors of the initial host response to @entity130 and constitute a significant threat to invading bacterial pathogens. The @entity1850 ( @entity1850 ) is characterised by significant host tissue injury mediated, in part, by uncontrolled regulation of PMN cytotoxic activity. We found that BLP-activated @entity1 PMN as evidenced by increased @entity9536 / @entity1454 ( @entity9536 ) expression. Up-regulation of PMN @entity9536 in response to BLP occurred independently of membrane-bound @entity5750 ( @entity5751 ). A similar up-regulation of @entity2071 ( @entity2071 ) on endothelial cells was observed whilst @entity4105 expression was unaffected. PMN transmigration across a @entity1 umbilical vein endothelial cell (HUVEC) monolayer was markedly increased after treating either PMN's or HUVEC independently with BLP. This increased transmigration did not occur as a result of any direct effect of BLP on HUVEC monolayer permeability, assessed objectively using the passage of @entity2823 -labeled Dextran-70. BLP primed PMN for enhanced respiratory burst and @entity224 anion production in response to @entity4515 , but did not influence phagocytosis of opsonized @entity526 . BLP far exceeds LPS as a gram-negative bacterial wall component, these findings therefore implicate BLP as an additional putative mediator of @entity1850 arising from gram-negative @entity281 .

Proinflammatory effects of bacterial lipoprotein on XXXX neutrophil activation status, function and cytotoxic potential in vitro.

@entity1 :: ('9606', 'Species') :: ['human'] @entity5750 :: ('929', 'Gene') :: ['CD14'] @entity526 :: ('562', 'Species') :: ['Escherichia coli'] @entity4515 :: ('CHEBI:60755', 'Chemical') :: ['PMA'] @entity4105 :: ('6401', 'Gene') :: ['E-Selectin'] @entity2823 :: ('MESH:D016650', 'Chemical') :: ['FITC'] @entity1454 :: ('3689', 'Gene') :: ['CD18'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity1850 :: ('MESH:D018746', 'Disease') :: ['systemic inflammatory response syndrome', 'SIRS'] @entity9536 :: ('3684', 'Gene') :: ['Mac-1', 'CD11b'] @entity5751 :: ('12475(Tax:10090)', 'Gene') :: ['mCD14'] @entity224 :: ('MESH:D013481', 'Chemical') :: ['superoxide'] @entity2071 :: ('3383', 'Gene') :: ['ICAM-1', 'intercellular adhesion molecule-1'] @entity130 :: ('MESH:D014947', 'Disease') :: ['injury or infection']
@entity1 :: (9606,Species) :: ['human']
